Expertise in
1
conditions

Dr. Goetz H. Kloecker

Hematology
Uofl Health-Brown Cancer Center
529 S Jackson St, 
Louisville, KY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
1
conditions
Uofl Health-Brown Cancer Center
529 S Jackson St, 
Louisville, KY 

Overview

Goetz Kloecker is a Hematologist practicing medicine in Louisville, Kentucky.

Dr. Kloecker is highly rated in 1 condition, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Sickle Cell Disease, Small Lymphocytic Lymphoma (SLL), Pediatric Low-Grade Glioma (pLGG), and Gastrostomy.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 14 clinical trials. Dr. Kloecker is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in KY

Hospital Affiliations

University Of Louisville Hospital
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Uofl Health-Brown Cancer Center
529 S Jackson St, Louisville, KY 40202

Additional Areas of Focus

Dr. Kloecker has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Biological, Drug
Study Drugs: Cobolimab, Dostarlimab, Docetaxel
Study Phase: Phase 2/Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 9 Less Clinical Trials

51 Total Publications

Artificial Intelligence Among US Hematology Oncology Fellows: A Multicenter Survey of Education, Attitudes, and Clinical Use.
Artificial Intelligence Among US Hematology Oncology Fellows: A Multicenter Survey of Education, Attitudes, and Clinical Use.
Journal: JCO oncology practice
Published: May 31, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Adam D. Lye
Hematology | Oncology
Expertise in
26
conditions
Dr. Adam D. Lye
Hematology | Oncology
Referral may be required

Norton Cancer Institute At Old Brownsboro Crossing

4955 Norton Healthcare Blvd, 
Louisville, KY 
 (10.2 miles away)
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Lye is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. He has been practicing medicine for over 19 years. Dr. Lye is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). Dr. Lye is board certified in American Board Of Internal Medicine, Medical Oncology - 2013 and American Board Of Internal Medicine, Internal Medicine - 2010. Dr. Lye is currently accepting new patients.

Expertise in
34
conditions
Expertise in
34
conditions
Referral may be required

Norton Healthcare Pavilion

315 E Broadway, 
Louisville, KY 
 (0.4 miles away)
502-629-2500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rodney Kosfeld is a Hematologist practicing medicine in Louisville, Kentucky. Dr. Kosfeld is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Myeloproliferative Neoplasms (MPN), Thrombocytopenia, Antiphospholipid Syndrome, and Multiple Myeloma. Dr. Kosfeld is currently accepting new patients.

Expertise in
22
conditions
Dr. Ashok B. Raj
Hematology | Oncology
Expertise in
22
conditions
Dr. Ashok B. Raj
Hematology | Oncology
Referral may be required

Norton Children's Sleep Medicine-Novak Center

411 E Chestnut St, 
Louisville, KY 
 (0.1 miles away)
502-588-3600
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Ashok Raj is a Hematologist and an Oncologist practicing medicine in Louisville, Kentucky. Dr. Raj is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobin SC Disease, Immune Thrombocytopenic Purpura (ITP), Bone Marrow Aspiration, and Lithotripsy. Dr. Raj is currently accepting new patients.

Frequently Asked Questions about Dr. Goetz H. Kloecker

How do I make an appointment with Dr. Goetz H. Kloecker?

You can book an appointment with Dr. Goetz H. Kloecker by calling their office at 502-562-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Goetz H. Kloecker a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Goetz H. Kloecker is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Goetz H. Kloecker specialize in?

While Dr. Goetz H. Kloecker is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Sickle Cell Disease, and Small Lymphocytic Lymphoma (SLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Goetz H. Kloecker participate in research or clinical trials?

Yes. Dr. Goetz H. Kloecker has published 51 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Goetz H. Kloecker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Goetz H. Kloecker accept my insurance?

Dr. Goetz H. Kloecker accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 502-562-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kloecker's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile